If you’ve been exploring medical weight loss options, you’ve likely encountered both semaglutide and tirzepatide. While both are GLP-1 receptor agonists that have revolutionized metabolic medicine, they work differently and produce different results. Understanding the distinction is key to choosing the right therapy for your goals.

What the Research Shows

Semaglutide acts selectively on GLP-1 receptors, demonstrating meaningful metabolic outcomes and an average 14-15% weight reduction across landmark clinical trials. Tirzepatide functions as a dual GIP/GLP-1 receptor agonist, engaging two complementary incretin pathways. In the SURMOUNT-1 clinical trial published in the New England Journal of Medicine, tirzepatide demonstrated substantial clinical efficacy for glycemic regulation and metabolic optimization. Individual response varies, and clinical suitability is determined through comprehensive lab review and physician consultation.

Bottom line: Both are highly effective. Tirzepatide generally produces greater weight loss (up to 20%+) due to its dual mechanism, while semaglutide has a longer track record and may be better tolerated by some patients. The right choice depends on your individual metabolic profile, goals, and tolerability.

What This Means at TRIM FITT

At TRIM FITT, every protocol is built on peer-reviewed evidence. Our physicians will review your labs and health history to recommend the right GLP-1 agent and titration schedule for your unique physiology. Book a consultation to find out which protocol is right for you.

Schedule Your TRIM FITT Consultation →

Educational purposes only. Not medical advice. Consult with a TRIM FITT provider before starting any treatment.